Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The lineup includes the Wegovy pill (oral semaglutide, FDA-approved December 2025, launched January 2026, the first FDA-approved oral GLP-1 for weight loss in adults), the Wegovy pen (injectable semaglutide 2.4 mg), Zepbound (tirzepatide via LillyDirect), and Ozempic (off-label for weight loss)
Revenue at Risk Calculations Calculating revenue at risk from patent cliffs requires distinguishing between nominal listed revenues and the net revenues after rebates and discounts
Hyperphagia defines the second stage, beginning with a heightened interest in food that progresses into a constant, intense drive to eat
Just as diabetic patients remain on metformin indefinitely because diabetes is a chronic condition, weight management patients may benefit from ongoing semaglutide use because obesity is similarly chronic
US$ 25.65
US$ 24.74
US$ 24.76
US$ 25.78
